Journal of Surgery Concepts & Practice >

2023 , Vol. 28 >Issue 04: 310 - 315

DOI: https://doi.org/10.16139/j.1007-9610.2023.04.007

Experts forum

Risk factors and prevention methods for post-ERCP pancreatitis

Expand
  • Department of Gastroenterology, Zhongnan Hospital of Wuhan University;Clinical Center and Key Lab of Intestinal and Colorectal Diseases of Hubei Province, Hubei Wuhan 430071, China

Received date: 2023-06-12

  Online published: 2023-10-24

Fold

Abstract

Endoscopic retrograde cholangio-pancreatography (ERCP) is one of the primary procedural techniques used for diagnosing biliary and pancreatic diseases. Post-ERCP pancreatitis (PEP) is the most common complication of ERCP, which resulted in prolonged hospitalization and potential risk of patients' lives, especially in severe cases. Understanding the risk factors associated with PEP is of paramount importance for its prevention. Currently, recognized risk factors for PEP encompass both patient-related factors and ERCP procedure-related factors. By considering these risk factors, implementing appropriate preoperative, intraoperative, and postoperative interventions could effectively reduce the incidence of PEP. In this article, we concisely summarized the common risk factors and preventive methods for PEP, offering valuable insights for healthcare professionals in clinical practice.

Key words： Endoscopic retrograde cholangio-pancreatography; Post-ERCP pancreatitis; Risk factor; Prevention

Cite this article

NIE Haihang, WANG Fan, WANG Hongling, ZHAO Qiu . Risk factors and prevention methods for post-ERCP pancreatitis[J]. Journal of Surgery Concepts & Practice, 2023 , 28(04) : 310 -315 . DOI: 10.16139/j.1007-9610.2023.04.007

References

[1] DUMONCEAU J M, ANDRIULLI A, ELMUNZER B J, et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) guideline - updated June 2014[J]. Endoscopy, 2014, 46(9):799-815.
[2] BUXBAUM J L, FREEMAN M, AMATEAU S K, et al. American Society for Gastrointestinal Endoscopy guideline on post-ERCP pancreatitis prevention strategies: methodology and review of evidence[J]. Gastrointest Endosc, 2023, 97(2):163-183.
[3] OBEIDAT A E, MAHFOUZ R, MONTI G, et al. Post-endoscopic retrograde cholangiopancreatography pancreatitis: what we already know[J]. Cureus, 2022, 14(1):e21773.
[4] JAMRY A. Risk factors of pancreatitis after endoscopic sphincterotomy. Review of literature and practical remarks based on approximately 10,000 ERCPs[J]. Pol Przegl Chir, 2017, 89(5):29-33.
[5] FREEMAN M L, DISARIO J A, NELSON D B, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study[J]. Gastrointest Endosc, 2001, 54(4):425-434.
[6] MADáCSY L, KURUCSAI G, FEJES R, et al. Prophylactic pancreas stenting followed by needle-knife fistulotomy in patients with sphincter of Oddi dysfunction and difficult cannulation: new method to prevent post-ERCP pancreatitis[J]. Dig Endosc, 2009, 21(1):8-13.
[7] 陈文华, 林军, 王剑屏, 等. ERCP术后胰腺炎的危险因素及预防措施[J]. 国际消化病杂志, 2018, 38(2):79-83.
[7] CHEN W H, LIN J, WANG J P, et al. Risk factors and preventive measures of post-ERCP pancreatitis[J]. Int J Dig Dis, 2018, 38(2):79-83.
[8] 李雄, 田宏伟, 龚世怡, 等. ERCP术后胰腺炎危险因素预防的研究进展[J]. 宁夏医科大学学报, 2023, 45(3):319-324.
[8] LI X, TIAN H W, GONG S Y, et al. Advances in the prevention of risk factors for pancreatitis after ERCP[J]. J Ningxia Med Univ, 2023, 45(3):319-324.
[9] PEKG?Z M. Post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review for prevention and treatment[J]. World J Gastroenterol, 2019, 25(29):4019-4042.
[10] MARTíNEZ-MONEO E, CáRDENAS-JAéN K, FERNáNDEZ-LASO A B, et al. Statin consumption and risk of post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Pancreatology, 2020, 20(5):801-805.
[11] SAITO H, KADONO Y, SHONO T, et al. Increased post-endoscopic retrograde cholangiopancreatography pancrea-titis for choledocholithiasis without acute cholangitis[J]. J Gastroenterol Hepatol, 2022, 37(2):327-334.
[12] CORWIN M T, LAMBA R, MCGAHAN J P. Functional MR cholangiography of the cystic duct and sphincter of Oddi using gadoxetate disodium: is a 30-minute delay long enough?[J]. J Magn Reson Imaging, 2013, 37(4):993-998.
[13] KUNWALD P, DREWES A M, KJAER D, et al. A new distensibility technique to measure sphincter of Oddi function[J]. Neurogastroenterol Motil, 2010, 22(9):978-983, e253.
[14] YAN X, ZHENG W, ZHANG Y, et al. Endoclip papillaplasty restores sphincter of Oddi function: pilot study[J]. Dig Endosc, 2021, 33(6):962-969.
[15] MENG Q Q, ZHAO S B, WANG Z J, et al. Incidence and risk factors for post-ERCP pancreatitis in pancreas divisum patients without chronic pancreatitis[J]. Scand J Gastroenterol, 2020, 55(6):732-736.
[16] TESTONI P A, VAILATI C, GIUSSANI A, et al. ERCP-induced and non-ERCP-induced acute pancreatitis: two distinct clinical entities with different outcomes in mild and severe form?[J]. Dig Liver Dis, 2010, 42(8):567-570.
[17] PARK C H, PARK S W, YANG M J, et al. Pre- and post-procedure risk prediction models for post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Surg Endosc, 2022, 36(3):2052-2061.
[18] TESTONI P A, MARIANI A, GIUSSANI A, et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study[J]. Am J Gastroenterol, 2010, 105(8):1753-1761.
[19] FACCIORUSSO A, RAMAI D, GKOLFAKIS P, et al. Comparative efficacy of different methods for difficult biliary cannulation in ERCP: systematic review and network meta-analysis[J]. Gastrointest Endosc, 2022, 95(1):60-71.e12.
[20] DUMONCEAU J M, ANDRIULLI A, DEVIERE J, et al. European Society of Gastrointestinal Endoscopy (ESGE) guideline: prophylaxis of post-ERCP pancreatitis[J]. Endoscopy, 2010, 42(6):503-515.
[21] ERGIN E, ORU? N, ERS?Z G, et al. Prognosis and risk factors of ERCP pancreatitis in elderly[J]. Sci Rep, 2021, 11(1):15930.
[22] KOHLI K, SAMANT H, KHAN K, et al. Risk stratification in post-ERCP pancreatitis: how do procedures, patient characteristics and clinical indicators influence outcomes?[J]. Pathophysiology, 2021, 28(1):76-85.
[23] YANG H, YANG Z, HONG J. Post-ERCP pancreatitis occurs more frequently in self-expandable metallic stents than multiple plastic stents on benign biliary strictures: a meta-analysis[J]. Ann Med, 2022, 54(1):2439-2449.
[24] 中华医学会消化内镜学分会, 中国医师协会胰腺病专业委员会. 内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见(2015年,上海)[J]. 中华消化内镜杂志, 2015, 32(12):794-799.
[24] Chinese Society of Digestive Endoscopy, Chinese Medical Association Pancreatic Disease Committee of Chinese Medical Doctor Association. Expert consensus statement on the pharmacologic prophylaxis of post ERCP pancrea-titis in China (2015, Shanghai)[J]. J Clin Hepatol, 2015, 32(12):794-799.
[25] NAWAZ M H, SARWAR S, NADEEM M A. Post-ERCP pancreatitis: risk factors and role of NSAIDs in primary prophylaxis[J]. Pak J Med Sci, 2020, 36(3):426-431.
[26] AKSHINTALA V S, SPERNA WEILAND C J, BHULLAR F A, et al. Non-steroidal anti-inflammatory drugs, intravenous fluids, pancreatic stents, or their combinations for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and network meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(9):733-742.
[27] GERACI G, PALUMBO V D, D'ORAZIO B, et al. Rectal diclofenac administration for prevention of post-endoscopic retrograde cholangio-pancreatography (ERCP) acute pancreatitis. Randomized prospective study[J]. Clin Ter, 2019, 170(5):e332-e336.
[28] MAKHZANGY H E, SAMY S, SHEHATA M, et al. Combined rectal indomethacin and intravenous saline hydration in post-ERCP pancreatitis prophylaxis[J]. Arab J Gastroenterol, 2022, 23(2):95-101.
[29] KATO K, SHIBA M, KAKIYA Y, et al. Celecoxib oral administration for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized prospective trial[J]. Pancreas, 2017, 46(7):880-886.
[30] ISHIWATARI H, URATA T, YASUDA I, et al. No benefit of oral diclofenac on post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Dig Dis Sci, 2016, 61(11):3292-3301.
[31] MáRTA K, GEDE N, SZAKáCS Z, et al. Combined use of indomethacin and hydration is the best conservative approach for post-ERCP pancreatitis prevention: a network meta-analysis[J]. Pancreatology, 2021, 21(7):1247-1255.
[32] RADADIYA D, BRAHMBHATT B, REDDY C, et al. Efficacy of combining aggressive hydration with rectal indomethacin in preventing post-ERCP pancreatitis: a systematic review and network meta-analysis[J]. J Clin Gastroenterol, 2022, 56(3):e239-e249.
[33] MAKHZANGY H E, SAMY S, SHEHATA M, et al. Combined rectal indomethacin and intravenous saline hydration in post-ERCP pancreatitis prophylaxis[J]. Arab J Gastroenterol, 2022, 23(2):95-101.
[34] HAJALIKHANI M, EMAMI M H, KHODADOOSTAN M, et al. Combination of diclofenac and aggressive hydration for the prevention of post-ERCP pancreatitis[J]. Gastroenterol Hepatol Bed Bench, 2018, 11(4):319-324.
[35] QIN X, LEI W S, XING Z X, et al. Prophylactic effect of somatostatin in preventing post-ERCP pancreatitis: an updated meta-analysis[J]. Saudi J Gastroenterol, 2015, 21(6):372-378.
[36] WANG G, XIAO G, XU L, et al. Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia: a systematic review and meta-analysis[J]. Pancreatology, 2018, 18(4):370-378.
[37] NOROUZI A, GHASEM POORI E, KAABE S, et al. Effect of adding intravenous somatostatin to rectal indomethacin on post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in high-risk patients: a double-blind randomized placebo-controlled clinical trial[J]. J Clin Gastroenterol, 2023, 57(2):204-210.
[38] BHATT H. Post-endoscopic retrograde cholangiopancreatography pancreatitis: an updated review of current preventive strategies[J]. Clin Exp Gastroenterol, 2021, 14:27-32.
[39] SHI Q Q, HUANG G X, LI W, et al. Rectal nonsteroidal anti-inflammatory drugs, glyceryl trinitrate, or combinations for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: a network meta-analysis[J]. World J Clin Cases, 2022, 10(22):7859-7871.
[40] WANG Y, XU B, ZHANG W, et al. Prophylactic effect of rectal indomethacin plus nitroglycerin administration for preventing pancreatitis after endoscopic retrograde cholangiopancreatography in female patients[J]. Ann Palliat Med, 2020, 9(6):4029-4037.
[41] KOHLI K, SAMANT H, KHAN K, et al. Risk stratification in post-ERCP pancreatitis: how do procedures, patient characteristics and clinical indicators influence outcomes?[J]. Pathophysiology, 2021, 28(1):76-85.
[42] MAZAKI T, MADO K, MASUDA H, et al. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: an updated meta-analysis[J]. J Gastroenterol, 2014, 49(2):343-355.
[43] AFGHANI E, AKSHINTALA V S, KHASHAB M A, et al. 3-Fr pancreatic stents for the prevention of post-ERCP pancreatitis in high-risk patients: a systematic review and network meta-analysis[J]. Endoscopy, 2014, 46(7):573-580.
[44] CHA S W, LEUNG W D, LEHMAN G A, et al. Does leaving a main pancreatic duct stent in place reduce the incidence of precut biliary sphincterotomy-associated pancreatitis? A randomized, prospective study[J]. Gastrointest Endosc, 2013, 77(2):209-216.
[45] CHOKSI N S, FOGEL E L, COTE G A, et al. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement[J]. Gastrointest Endosc, 2015, 81(1):150-155.
[46] TSE F, YUAN Y, MOAYYEDI P, et al. Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis[J]. Endoscopy, 2013, 45(8):605-618.
[47] TSE F, YUAN Y, MOAYYEDI P, et al. Double-guidewire technique in difficult biliary cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis[J]. Endoscopy, 2017, 49(1):15-26.
Options
Outlines

/

〈 〉